Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q3 2026 › vs Q2 2026
Lexicon Pharmaceuticals (LXRX) Q3 2026 vs Q2 2026 (quarter over quarter)
Lexicon Pharmaceuticals's revenue rose $10.6M (16×) from $692K in Q2 2026 to $11.2M in Q3 2026.
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $11.2M | $692K | $10.6M | 16× |
| Other income, net | $490K | −$5.2M | $5.7M | — |
| Net loss | $14.0M | $31.8M | −$17.8M | -56% |
| Costs & expenses | $25.7M | $32.5M | −$6.7M | -21% |
| Operating costs | $25.7M | $27.2M | −$1.5M | -5% |
| Cost of revenue | $79K | $39K | $40K | +103% |
| Research & development | $16.2M | $17.4M | −$1.2M | -7% |
| SG&A | $9.5M | $9.8M | −$288K | -3% |
| Operating cash sources | $14.0M | $31.8M | −$17.8M | -56% |
| Depreciation & amortization | $95K | $102K | −$7K | -7% |
| Share-based compensation | $3.4M | $3.3M | $47K | +1% |
| Working capital & other | $2.4M | $19.1M | −$16.7M | -87% |
| Cash used in operations | $8.1M | $9.2M | −$1.1M | -12% |
| Net loss absorbed | $14.0M | $31.8M | −$17.8M | -56% |
Questions
How much did Lexicon Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Lexicon Pharmaceuticals's revenue rose $10.6M (16×) from $692K in Q2 2026 to $11.2M in Q3 2026.